778. Modeling Likelihood of Coverage for Narrow Spectrum Antibiotics in Patients Hospitalized with Urinary Tract Infections
Session: Poster Abstract Session: Treatment of Resistant Infections - Clinical Analyses
Thursday, October 5, 2017
Room: Poster Hall CD

When prescribing empiric antibiotics, providers try to choose the narrowest spectrum antibiotic that will cover a patient’s infection. To do this they must assess the likelihood of coverage of different regimens. We developed a model for cefazolin (or cephalexin) coverage for patients admitted to the hospital with urinary tract infections (UTI), to identify agroup of patients with a high likelihood of coverage by this first-line, narrow spectrum antibiotic. We also compared cefazolin coverage to the coverage of patients' actual empiric treatment regimens.


Patients admitted from 11/1/11 to 1/1/14 with a positive urine culture in the 1st 48 hours and a discharge diagnosis of UTI, were included in the dataset. Data extracted from our information warehouse included empiric antibiotic administration data, demographics, comorbidities, and past antibiotic use. Only the first eligible admission for each patient was included. A 20% random sample of patients was selected as the validation set. Logistic regression models estimated the predicted probability of cefazolin coverage.


A total of 3,456 patients with an eligible UTI were included. Six hundred and ninety one (691) were held out for validation. Cefazolin covered 49% of the UTIs. The final model had an area under the receiver operating curve (AUC) of 69% (95% CI: 67%, 71%) in the test and 70%, (66%, 74%) in the validation set. Overall 49/65 (75%) in the highest estimated decile of cefazolin coverage had a UTI that would have been covered; only 13/66 (20%) in the lowest decile would have been covered. Of the patients in the highest decile of cefazolin coverage, 48/65 (74%) were covered by the actual empiric regimen given, however 35/65 (54%) of those regimens consisted of multiple antibiotics, and of those patients who would have been covered by cefazolin, 36/49 (73%) were empirically treated with broader spectrum antibiotics.


Our findings suggest that the model can reasonably identify patients whose infections would be likely to be covered by cefazolin. Further, the majority of patients would have been covered by a narrower spectrum antibiotics than what they received.

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award Number R01AI116975.

Courtney Hebert, MD, MS, Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, OH, Erinn Hade, PhD, Biomedical Informatics, The Ohio State University, Columbus, OH, Protiva Rahman, BS, The Ohio State University, Columbus, OH, Mark Lustberg, MD, PhD, Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Kurt Stevenson, MD, MPH, FSHEA, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, OH and Preeti Pancholi, PhD, Clinical Microbiology, The Ohio State Univ Med Ctr, Columbus, OH


C. Hebert, None

E. Hade, None

P. Rahman, None

M. Lustberg, None

K. Stevenson, None

P. Pancholi, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.